8-K: Pyxis Oncology Stockholders Elect Directors and Ratify Auditor at Annual Meeting

Pyxis Oncology, Inc. announced the successful election of three Class I directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Summary

• Pyxis Oncology, Inc. held its Annual Meeting of Stockholders virtually on June 18, 2025, at 09:00 a.m. Eastern Daylight Time.
• As of the record date, April 21, 2025, there were 61,947,665 shares of common stock outstanding and entitled to vote.
• A quorum was present at the meeting with 43,996,450 shares of common stock represented.
• Stockholders elected Dr. Santhosh Palani, Ph.D., CFA, Mr. Darren Cline, and Dr. Rachel Humphrey, M.D. as Class I directors to serve until the Company's 2028 Annual Meeting of Stockholders.
• The votes for the director nominees were: Dr. Santhosh Palani (22,056,449 For, 7,314,363 Withheld), Mr. Darren Cline (22,028,914 For, 7,341,898 Withheld), and Dr. Rachel Humphrey (21,357,102 For, 8,013,710 Withheld), with 14,625,638 Broker Non-Votes for each nominee.
• Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The votes for the auditor ratification were: 43,733,259 For, 233,563 Against, and 29,628 Abstain, with no Broker Non-Votes.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals presented at the Annual Meeting were approved by the stockholders, indicating stable corporate governance and successful execution of routine corporate procedures.

Positives

• All proposed Class I directors (Dr. Santhosh Palani, Mr. Darren Cline, and Dr. Rachel Humphrey) were successfully elected with a majority of votes.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm was overwhelmingly ratified by stockholders, indicating strong support for the company's financial oversight.

Future Outlook

The document indicates that the newly elected Class I directors will serve until the Company's 2028 Annual Meeting of Stockholders.

Industry Context

This filing is a routine corporate governance update, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or oncology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Voted on key corporate governance matters, including director elections and auditor ratification, directly influencing the company's oversight and accountability.

Next Steps

• The elected Class I directors will serve until the Company's 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Annual Meeting, Stockholders, Director Election, Auditor Ratification, Corporate Governance, Proxy Vote, SEC Filing, 8-K, Pyxis Oncology